Co-Diagnostics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Brown Brian Lee, was filed 21 Mar 2023.
Since the insiders bought
- -28.2%Entry US$48.90 · Close at T+365 US$35.10
- -45.0%Entry US$51.00 · Close at T+365 US$28.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 680 shares@ US$5.070.064% mcap66.0% of flowCommon StockSEC:0002016256-26-000002:1
- 1,633 shares@ US$5.070.15% mcap39.3% of flowCommon StockSEC:0001712187-26-000002:1
- 1,350 shares@ US$5.070.13% mcap27.4% of flowCommon StockSEC:0001847811-26-000002:1
- 1,890 shares0Common StockSEC:0002016256-26-000002:0
- 3,750 shares0Common StockSEC:0001847811-26-000002:0
- 1,695 shares0Common StockSEC:0001296764-26-000002:0
- 1,695 shares0Common StockSEC:0001589502-26-000002:0
- 4,584 shares0Common StockSEC:0001712187-26-000002:0
- 1,695 shares0Common StockSEC:0001794564-26-000002:0
- 1,695 shares0Common StockSEC:0001812942-26-000002:0
- 49,575 shares@ US$0.350.6% of flowCommon StockSEC:0001712187-25-000002:1
- 17,200 shares@ US$0.3533.5% of flowCommon StockSEC:0002016256-25-000002:1
- 40,723 shares@ US$0.353.6% of flowCommon StockSEC:0001847811-25-000002:1
- 56,667 shares0Common StockSEC:0002016256-25-000002:0
- 57,499 shares0Common StockSEC:0001812942-25-000002:0
- 57,499 shares0Common StockSEC:0001794564-25-000002:0
- 57,499 shares0Common StockSEC:0001589502-25-000002:0
- 134,167 shares0Common StockSEC:0001847811-25-000002:0
- 57,499 shares0Common StockSEC:0001296764-25-000002:0
- 163,333 shares0Common StockSEC:0001712187-25-000002:0
- 48,334 shares0Common StockSEC:0001562180-25-004194:0
- 48,334 shares0Common StockSEC:0001562180-25-004195:0
- 20,000 shares0Common StockSEC:0001562180-25-004198:0
- 7,180 shares@ US$0.2434.0% of flowCommon StockSEC:0001562180-25-004198:1
- 48,161 shares@ US$0.2447.7% of flowCommon StockSEC:0001562180-25-004199:1
25 of 147 declarations
About Co-Diagnostics, Inc.
At Co-Diagnostics, Inc., sales weigh far more than purchases: 22 sales (15 with an amount) for EUR 3,606,363, median EUR 98,737, against 6 purchases for just EUR 13,728, median EUR 1,410. Purchases are only 21% of open-market trades. The largest sales are by Reed L. Benson, filed as CFO and secretary (EUR 789,884 on November 25, 2020), then as general counsel (EUR 681,811 on May 19, 2021), and by Dwight H. Egan, chief executive officer (EUR 629,656 on November 23, 2020).
The purchases are small: Brian Lee Brown, chief financial officer, EUR 5,335 on March 20, 2023; Brent Satterfield, chief science officer, EUR 3,993 on April 9, 2018 and EUR 1,993 on May 11, 2018.
Read moreShow less
Twelve insiders have filed 147 times since December 18, 2017, with 27 in 2020 and 26 in 2021. Dwight H. Egan signs 34, 4 of them sales; Eugene Durenard, a director, 20, 7 of them sales. The record holds 76 grants and 14 option exercises. Over the last twelve months there are 20 filings, with no purchase or sale. Market capitalisation is USD 4,694,937, and insiders hold 1.9%.
